Form 4: Certara Executive Patrick F. Smith Reports Changes in Beneficial Ownership

Patrick F. Smith, President of Drug Development Solutions at Certara, Inc., reports transactions involving restricted stock units and common stock, resulting in adjustments to his beneficial ownership.

Summary

• On April 1, 2024, Patrick F. Smith, President of Drug Development Solutions at Certara, Inc., engaged in transactions involving Certara's common stock and restricted stock units (RSUs).
• These transactions included the vesting and settlement of RSUs granted in 2021, 2022 and 2023 under the company's 2020 Incentive Plan.
• Tax obligations related to the vesting of these RSUs were satisfied through the withholding of shares.
• Smith also acquired 30,381 new RSUs that will vest in three equal installments from April 1, 2025, to April 1, 2027.
• Following these transactions, Smith's total beneficial ownership includes 64,518 shares of common stock and 30,381 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing detailing stock transactions. The granting of RSUs is generally positive, but the tax withholding is a neutral event.

Positives

• The granting of new RSUs to a key executive could be seen as a positive sign of the company's commitment to retaining talent.
• The vesting of RSUs indicates that performance milestones have been met, which could be viewed favorably.

Negatives

• The withholding of shares to cover tax obligations could be interpreted as a slight dilution of existing shareholders' equity.

Risks

• Fluctuations in the stock price could impact the value of the RSUs and the overall compensation of the executive.
• Changes in tax laws could affect the tax implications of RSU vesting and settlement.

Future Outlook

The document outlines the vesting schedule for RSUs granted to the reporting person, indicating future dates for potential stock issuance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the alignment of management's interests with those of shareholders.

Comparison to Industry Standards

• Stock-based compensation, including RSUs, is a common practice among publicly traded companies, especially in the technology and pharmaceutical sectors, to incentivize and retain key employees.
• The vesting schedules and terms of the 2020 Incentive Plan are likely comparable to those offered by peer companies in the industry.
• Companies like ICON plc and Medpace Holdings, Inc. also utilize stock-based compensation as part of their overall executive compensation packages.

Stakeholder Impact

• Shareholders may be interested in the details of executive compensation and stock ownership.
• Employees may view the granting of RSUs as a positive sign of the company's commitment to its workforce.

Key Dates